Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. In this multicentre, randomised, double-b...
Saved in:
| Published in | Lancet neurology Vol. 15; no. 4; pp. 382 - 390 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.04.2016
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.
In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18–60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered with ClinicalTrials.gov, number NCT01952574. An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334.
From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was −3·4 (SE 0·4) days with AMG 334 70 mg versus −2·3 (0·3) days with placebo (difference −1·1 days [95% CI −2·1 to −0·2], p=0·021). The mean reductions in monthly migraine days with the 7 mg (−2·2 [SE 0·4]) and the 21 mg (−2·4 [0·4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded.
These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials.
Amgen. |
|---|---|
| AbstractList | Summary Background The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. Methods In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18–60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered with ClinicalTrials.gov , number NCT01952574 . An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334. Findings From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was −3·4 (SE 0·4) days with AMG 334 70 mg versus −2·3 (0·3) days with placebo (difference −1·1 days [95% CI −2·1 to −0·2], p=0·021). The mean reductions in monthly migraine days with the 7 mg (−2·2 [SE 0·4]) and the 21 mg (−2·4 [0·4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded. Interpretation These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials. Funding Amgen. The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered with ClinicalTrials.gov, number NCT01952574. An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334. From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was -3·4 (SE 0·4) days with AMG 334 70 mg versus -2·3 (0·3) days with placebo (difference -1·1 days [95% CI -2·1 to -0·2], p=0·021). The mean reductions in monthly migraine days with the 7 mg (-2·2 [SE 0·4]) and the 21 mg (-2·4 [0·4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded. These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials. Amgen. Background The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. Methods In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered with ClinicalTrials.gov, number NCT01952574. An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334. Findings From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was -3.4 (SE 0.4) days with AMG 334 70 mg versus -2.3 (0.3) days with placebo (difference -1.1 days [95% CI -2.1 to -0.2], p=0.021). The mean reductions in monthly migraine days with the 7 mg (-2.2 [SE 0.4]) and the 21 mg (-2.4 [0.4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded. Interpretation These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials. Funding Amgen. The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18–60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered with ClinicalTrials.gov, number NCT01952574. An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334. From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was −3·4 (SE 0·4) days with AMG 334 70 mg versus −2·3 (0·3) days with placebo (difference −1·1 days [95% CI −2·1 to −0·2], p=0·021). The mean reductions in monthly migraine days with the 7 mg (−2·2 [SE 0·4]) and the 21 mg (−2·4 [0·4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded. These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials. Amgen. The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention. Methods In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North America and Europe, and randomly assigned in a 3:2:2:2 ratio to monthly subcutaneous placebo, AMG 334 7 mg, AMG 334 21 mg, or AMG 334 70 mg using a sponsor-generated randomisation sequence centrally executed by an interactive voice response or interactive web response system. Study site personnel, patients, and the sponsor study personnel were masked to the treatment assignment. The primary endpoint was the change in monthly migraine days from baseline to the last 4 weeks of the 12-week double-blind treatment phase. The primary endpoint was calculated using the least squares mean at each timepoint from a generalised linear mixed-effect model for repeated measures. Safety endpoints were adverse events, clinical laboratory values, vital signs, and anti-AMG 334 antibodies. The study is registered withClinicalTrials.gov, numberNCT01952574. An open-label extension phase of up to 256 weeks is ongoing and will assess the long-term safety of AMG 334. Findings From Aug 6, 2013, to June 30, 2014, 483 patients were randomly assigned to placebo (n=160), AMG 334 7 mg (n=108), AMG 334 21 mg (n=108), or AMG 334 70 mg (n=107). The mean change in monthly migraine days at week 12 was -3·4 (SE 0·4) days with AMG 334 70 mg versus -2·3 (0·3) days with placebo (difference -1·1 days [95% CI -2·1 to -0·2], p=0·021). The mean reductions in monthly migraine days with the 7 mg (-2·2 [SE 0·4]) and the 21 mg (-2·4 [0·4]) doses were not significantly different from that with placebo. Adverse events were recorded in 82 (54%) patients who received placebo, 54 (50%) patients in the AMG 334 7 mg group, 54 (51%) patients in the AMG 334 21 mg group, and 57 (54%) patients in the AMG 334 70 mg group. The most frequently reported adverse events were nasopharyngitis, fatigue, and headache. Serious adverse events were reported for one patient in the AMG 334 7 mg group (ruptured ovarian cyst) and one patient in the AMG 334 70 mg group (migraine and vertigo); these events were judged to be unrelated to AMG 334 treatment. Nine (3%) of 317 patients had neutralising antibodies. No apparent association was recorded between patients with positive anti-AMG 334 antibodies and adverse events. No clinically significant vital signs, laboratory, or electrocardiogram findings were recorded. Interpretation These results suggest that AMG 334 70 mg might be a potential therapy for migraine prevention in patients with episodic migraine and support further investigation of AMG 334 in larger phase 3 trials. Funding Amgen. |
| Author | Sun, Hong Chon, Yun Reuter, Uwe Silberstein, Stephen Goadsby, Peter J Dietrich, Julie Dodick, David W Ashina, Messoud Saper, Joel Cady, Roger Lenz, Robert |
| Author_xml | – sequence: 1 givenname: Hong surname: Sun fullname: Sun, Hong organization: Department of Global Development, Amgen, Thousand Oaks, CA, USA – sequence: 2 givenname: David W surname: Dodick fullname: Dodick, David W organization: Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA – sequence: 3 givenname: Stephen surname: Silberstein fullname: Silberstein, Stephen organization: Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA – sequence: 4 givenname: Peter J surname: Goadsby fullname: Goadsby, Peter J organization: Department of Neurology NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, London, UK – sequence: 5 givenname: Uwe surname: Reuter fullname: Reuter, Uwe organization: Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany – sequence: 6 givenname: Messoud surname: Ashina fullname: Ashina, Messoud organization: Department of Neurology, Danish Headache Center and Department of Neurology, Rigshospitalet, Faculty of Medical and Health Sciences, University of Copenhagen, Copenhagen, Denmark – sequence: 7 givenname: Joel surname: Saper fullname: Saper, Joel organization: Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA – sequence: 8 givenname: Roger surname: Cady fullname: Cady, Roger organization: Clinvest Research, Banyan Group, Headache Care Center, Springfield, MO, USA – sequence: 9 givenname: Yun surname: Chon fullname: Chon, Yun organization: Department of Biostatistics, Amgen, Thousand Oaks, CA, USA – sequence: 10 givenname: Julie surname: Dietrich fullname: Dietrich, Julie organization: Department of Global Development, Amgen, Thousand Oaks, CA, USA – sequence: 11 givenname: Robert surname: Lenz fullname: Lenz, Robert email: rlenz@amgen.com organization: Department of Global Development, Amgen, Thousand Oaks, CA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26879279$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUl1rFDEUHaRiP_QnKAFfWnA0X5OZrWgpRatQ8aH6HDLJjaZmkzGZKeyj_9zM7lZhQWpecm9yzsnlnBxWeyEGqKqnBL8kmIhX14S3vOac0mMiTjDGZFGzB9XB9lg0e39qSverw5xvMKaEd-RRtU9F1y5ouziofl0rC-MKqWAQWOu00isULTr_dIkY48jGhIYEtxBGF8N8A4PL0TiNlu5bUi7AKVIoFX5cugzmBTJx6j3UvXehdINXGvpY6xjGFL2fEcN3lQFRNCan_OPqoVU-w5PtflR9ff_uy8WH-urz5ceL86taC0bGmhvDgQvGSc9KTQXuGqGatjGiUcJa2wndiJ4KZoRueWcb3WuDFbaMadMv2FF1vNEdUvw5QR5lmVeD9ypAnLIkbSvKWjBWoM93oDdxSqFMN6NoxxtKSUE926KmfglGDsktVVrJO3ML4PUGoFPMOYGV2o1q9nEsxnlJsJyjlOso5ZyTLN06SjkP0eyw7x64j3e24UEx89ZBklk7CBqMS6BHaaK7V-HtjoIuWZav4X_ACvJfL2SmEm9EZg0i1gqzwJt_C_zHAL8Bd7zcGA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1007_s11095_017_2183_6 crossref_primary_10_1177_0271678X17733655 crossref_primary_10_1007_s11739_016_1489_4 crossref_primary_10_1212_WNL_0000000000008743 crossref_primary_10_1007_s40259_017_0250_5 crossref_primary_10_1038_nrd_2017_91 crossref_primary_10_1177_0333102418759786 crossref_primary_10_1097_WNF_0000000000000227 crossref_primary_10_1007_s40261_022_01230_x crossref_primary_10_1007_s40265_019_01069_1 crossref_primary_10_1093_pm_pnad141 crossref_primary_10_1080_14737175_2019_1565996 crossref_primary_10_1177_1744806918820452 crossref_primary_10_1002_wnan_1427 crossref_primary_10_1111_head_14208 crossref_primary_10_1177_03331024231206162 crossref_primary_10_1111_ene_15260 crossref_primary_10_1186_s10194_018_0927_2 crossref_primary_10_1089_ars_2017_7260 crossref_primary_10_1177_03331024221144783 crossref_primary_10_1126_scisignal_abe1648 crossref_primary_10_1177_0333102419896539 crossref_primary_10_1007_s00281_018_0673_1 crossref_primary_10_1016_j_tips_2016_06_002 crossref_primary_10_1111_bph_13917 crossref_primary_10_3390_ph12020054 crossref_primary_10_1080_14728214_2018_1552939 crossref_primary_10_1177_1744806917740233 crossref_primary_10_1111_head_13907 crossref_primary_10_15406_emij_2018_06_00166 crossref_primary_10_1016_S1474_4422_16_00040_5 crossref_primary_10_1007_s13311_018_0622_7 crossref_primary_10_1212_WNL_0000000000010019 crossref_primary_10_1007_s40273_020_00996_2 crossref_primary_10_1186_s10194_021_01267_x crossref_primary_10_1001_jamaneurol_2021_4678 crossref_primary_10_1186_s10194_018_0955_y crossref_primary_10_3390_futurepharmacol3010008 crossref_primary_10_1186_s10194_022_01514_9 crossref_primary_10_30629_2658_7947_2021_26_3_4_14 crossref_primary_10_1177_0333102416681571 crossref_primary_10_1177_03331024211018137 crossref_primary_10_1186_s12874_019_0664_5 crossref_primary_10_1007_s10072_017_2907_8 crossref_primary_10_1016_S0140_6736_19_32504_8 crossref_primary_10_3390_ph14070700 crossref_primary_10_1056_NEJMoa1705848 crossref_primary_10_1186_s10194_019_1018_8 crossref_primary_10_3390_ijms221910325 crossref_primary_10_1016_j_psychres_2024_115786 crossref_primary_10_5604_01_3001_0054_4389 crossref_primary_10_1177_0333102419829007 crossref_primary_10_1186_s12883_022_02710_5 crossref_primary_10_1111_head_13147 crossref_primary_10_1177_25158163221120103 crossref_primary_10_1212_CPJ_0000000000000654 crossref_primary_10_1186_s10194_022_01526_5 crossref_primary_10_1186_s10194_018_0905_8 crossref_primary_10_3390_ijms241511993 crossref_primary_10_1002_acn3_302 crossref_primary_10_1016_S1474_4422_22_00294_0 crossref_primary_10_4155_tde_2021_0028 crossref_primary_10_1177_0333102418821662 crossref_primary_10_1016_j_nbd_2022_105946 crossref_primary_10_1186_s10194_021_01292_w crossref_primary_10_1111_head_13929 crossref_primary_10_1016_j_nrl_2020_10_009 crossref_primary_10_1007_s00415_017_8434_y crossref_primary_10_1007_s11739_020_02407_y crossref_primary_10_1016_j_pharep_2019_03_002 crossref_primary_10_1111_head_13379 crossref_primary_10_1111_head_13018 crossref_primary_10_1093_pm_pnx108 crossref_primary_10_1007_s40259_021_00469_8 crossref_primary_10_2217_fnl_2016_0006 crossref_primary_10_1016_j_intimp_2022_109366 crossref_primary_10_1007_s11916_017_0628_6 crossref_primary_10_1016_j_ejmech_2022_114962 crossref_primary_10_1097_WCO_0000000000000548 crossref_primary_10_2174_1871527320666211011110307 crossref_primary_10_3988_jcn_2023_0311 crossref_primary_10_5604_01_3001_0013_4581 crossref_primary_10_1002_14651858_CD015505 crossref_primary_10_2174_1871527319666200618144637 crossref_primary_10_1111_head_14655 crossref_primary_10_1016_j_crneur_2023_100093 crossref_primary_10_1186_s10194_019_1067_z crossref_primary_10_1186_s10194_022_01523_8 crossref_primary_10_3390_ijms22052688 crossref_primary_10_2217_pmt_2021_0077 crossref_primary_10_1111_head_14096 crossref_primary_10_5604_01_3001_0014_4591 crossref_primary_10_1186_s10194_017_0811_5 crossref_primary_10_1186_s10194_021_01335_2 crossref_primary_10_1016_S1474_4422_17_30083_2 crossref_primary_10_1097_AJP_0000000000001136 crossref_primary_10_1016_j_nrl_2019_03_013 crossref_primary_10_1136_bmjopen_2022_068616 crossref_primary_10_3389_fneur_2024_1415760 crossref_primary_10_2174_0929867325666180530114534 crossref_primary_10_3389_fneur_2024_1402569 crossref_primary_10_1111_cts_13755 crossref_primary_10_1007_s10072_017_2910_0 crossref_primary_10_1111_head_13316 crossref_primary_10_1016_j_ncl_2020_09_001 crossref_primary_10_3389_fnmol_2023_1182515 crossref_primary_10_1111_head_13432 crossref_primary_10_1007_s13311_017_0596_x crossref_primary_10_1590_0004_282x20190004 crossref_primary_10_17116_jnevro202212202174 crossref_primary_10_3389_fphys_2022_825992 crossref_primary_10_1177_03331024211010308 crossref_primary_10_1186_s10194_017_0807_1 crossref_primary_10_1017_cjn_2024_285 crossref_primary_10_3389_fphar_2017_00740 crossref_primary_10_1080_14728214_2023_2207819 crossref_primary_10_4103_aian_aian_199_22 crossref_primary_10_1177_0333102419877169 crossref_primary_10_1016_S1474_4422_16_30338_6 crossref_primary_10_1111_head_14679 crossref_primary_10_3310_AYWA5297 crossref_primary_10_1016_j_jpsychores_2018_06_012 crossref_primary_10_1016_j_neuropharm_2018_07_017 crossref_primary_10_1177_03331024211024160 crossref_primary_10_3390_ph15101189 crossref_primary_10_1016_j_clineuro_2017_01_009 crossref_primary_10_3390_jcm13071964 crossref_primary_10_1186_s12955_019_1242_6 crossref_primary_10_1097_01_TPM_0000554657_54670_d5 crossref_primary_10_1016_j_neuroscience_2016_04_046 crossref_primary_10_1111_ene_14715 crossref_primary_10_1371_journal_pone_0286453 crossref_primary_10_4103_joacp_JOACP_3_19 crossref_primary_10_1177_0333102417702120 crossref_primary_10_1186_s10194_022_01431_x crossref_primary_10_1007_s10072_018_3547_3 crossref_primary_10_1111_head_13456 crossref_primary_10_1177_1060028020903417 crossref_primary_10_1007_s11916_018_0686_4 crossref_primary_10_1111_head_14423 crossref_primary_10_1177_0333102417747230 crossref_primary_10_1186_s10194_023_01594_1 crossref_primary_10_1093_brain_aww236 crossref_primary_10_1007_s10072_021_05861_4 crossref_primary_10_1177_0333102417712719 crossref_primary_10_2174_1381612825666190709204107 crossref_primary_10_1016_j_nrleng_2019_03_025 crossref_primary_10_1523_JNEUROSCI_2211_17_2017 crossref_primary_10_1212_WNL_0000000000007497 crossref_primary_10_2169_internalmedicine_4037_24 crossref_primary_10_1007_s40265_018_0944_0 crossref_primary_10_1186_s10194_022_01424_w crossref_primary_10_2169_naika_106_1773 crossref_primary_10_1136_dtb_2020_000037 crossref_primary_10_1016_j_pharmthera_2020_107528 crossref_primary_10_1111_head_14291 crossref_primary_10_1007_s40267_018_0589_9 crossref_primary_10_1080_17425255_2018_1416097 crossref_primary_10_1186_s10194_021_01333_4 crossref_primary_10_1177_0333102418801579 crossref_primary_10_1002_cpdd_345 crossref_primary_10_1016_S1474_4422_20_30234_9 crossref_primary_10_1177_0333102419854082 crossref_primary_10_17340_jkna_2020_2_2 crossref_primary_10_1177_0271678X17751352 crossref_primary_10_1186_s10194_017_0750_1 crossref_primary_10_1177_0333102420960020 crossref_primary_10_1002_sim_7817 crossref_primary_10_1016_j_nrleng_2020_10_008 crossref_primary_10_1007_s10072_018_3337_y crossref_primary_10_1017_S1092852917000864 crossref_primary_10_1007_s40263_019_00665_9 crossref_primary_10_1111_head_13078 crossref_primary_10_1007_s11940_017_0463_4 crossref_primary_10_1093_nutrit_nuab080 crossref_primary_10_7759_cureus_13002 crossref_primary_10_1080_17425255_2021_1856366 crossref_primary_10_1186_s10194_022_01511_y crossref_primary_10_2217_pmt_2018_0037 crossref_primary_10_1111_head_13076 crossref_primary_10_1038_s41598_020_75602_8 crossref_primary_10_1177_03331024221075621 crossref_primary_10_1177_20503121221128688 crossref_primary_10_2147_TCRM_S263825 crossref_primary_10_1186_s10194_024_01830_2 crossref_primary_10_1212_WNL_0000000000012029 crossref_primary_10_1097_PR9_0000000000000565 crossref_primary_10_1186_s10194_023_01611_3 crossref_primary_10_3389_fphar_2023_1257282 crossref_primary_10_1007_s40259_022_00530_0 crossref_primary_10_1177_25158163241267310 crossref_primary_10_1111_head_13302 crossref_primary_10_1111_head_13305 crossref_primary_10_1080_14740338_2021_1933941 crossref_primary_10_1016_S0140_6736_18_30478_1 crossref_primary_10_1016_S1474_4422_17_30126_6 crossref_primary_10_1186_s10194_018_0909_4 crossref_primary_10_1097_WCO_0000000000000689 crossref_primary_10_7759_cureus_8711 crossref_primary_10_2174_1570159X19666210823104916 crossref_primary_10_1080_14737175_2016_1216796 crossref_primary_10_1097_WCO_0000000000000438 crossref_primary_10_1007_s10286_017_0468_9 crossref_primary_10_1007_s40120_021_00250_7 crossref_primary_10_1111_head_13529 crossref_primary_10_1177_0333102420912726 crossref_primary_10_1002_psp4_13048 crossref_primary_10_1007_s15006_017_0284_0 crossref_primary_10_3390_ijms20143527 crossref_primary_10_1080_14740338_2022_2049231 crossref_primary_10_1111_head_14068 crossref_primary_10_1097_j_pain_0000000000001007 crossref_primary_10_1111_head_13652 crossref_primary_10_1177_0333102420970523 crossref_primary_10_1097_j_pain_0000000000000831 crossref_primary_10_1097_MD_0000000000018483 crossref_primary_10_4103_0028_3886_315997 crossref_primary_10_1177_0333102416684344 crossref_primary_10_1177_03331024241299377 crossref_primary_10_1177_0018578718797295 crossref_primary_10_1177_0333102417741297 crossref_primary_10_1097_01_NT_0000491142_84599_1d crossref_primary_10_1007_s11916_025_01365_4 crossref_primary_10_1007_s13311_022_01230_x crossref_primary_10_1080_14740338_2020_1811229 crossref_primary_10_1186_s12967_020_02681_6 crossref_primary_10_1177_0333102419877663 crossref_primary_10_3389_fphys_2021_820006 crossref_primary_10_1111_head_14138 crossref_primary_10_1111_head_13601 crossref_primary_10_1007_s15006_019_0021_y crossref_primary_10_1016_j_praneu_2018_01_015 crossref_primary_10_1007_s40265_018_0865_y crossref_primary_10_1177_1179069517726996 crossref_primary_10_1007_s15005_016_1960_9 crossref_primary_10_1111_head_14921 crossref_primary_10_17925_ENR_2019_14_2_68 crossref_primary_10_1111_head_13951 crossref_primary_10_1177_0333102418776017 crossref_primary_10_1186_s10194_020_01211_5 crossref_primary_10_1111_head_14007 crossref_primary_10_1186_s10194_019_0994_z crossref_primary_10_1111_head_14485 crossref_primary_10_1111_head_13154 crossref_primary_10_1186_s13005_025_00494_w crossref_primary_10_1212_CPJ_0000000000200373 crossref_primary_10_1016_j_npep_2016_11_004 crossref_primary_10_1136_bmjno_2023_000616 crossref_primary_10_1177_0333102419888222 crossref_primary_10_1007_s11916_017_0648_2 crossref_primary_10_1080_14740338_2021_1866537 crossref_primary_10_1080_14728222_2020_1724285 crossref_primary_10_1080_01616412_2024_2354618 crossref_primary_10_1186_s10194_017_0741_2 crossref_primary_10_1590_0004_282x_anp_2022_s112 crossref_primary_10_1523_JNEUROSCI_2967_16_2016 crossref_primary_10_1007_s11916_018_0693_5 crossref_primary_10_1080_14737175_2016_1200973 crossref_primary_10_1186_s10194_019_1024_x crossref_primary_10_1080_17425255_2021_1982892 crossref_primary_10_1021_acsptsci_9b00061 crossref_primary_10_1007_s10072_017_2924_7 crossref_primary_10_1111_head_13064 crossref_primary_10_1152_physrev_00034_2015 crossref_primary_10_1515_tnsci_2020_0201 crossref_primary_10_1038_nrdp_2018_6 crossref_primary_10_1186_s12883_020_01633_3 crossref_primary_10_1177_0333102418784698 crossref_primary_10_1007_s12325_022_02386_w crossref_primary_10_1186_s10194_018_0832_8 crossref_primary_10_1177_1060028019835166 crossref_primary_10_1212_WNL_0000000000004391 crossref_primary_10_1007_s40265_018_0923_5 crossref_primary_10_1111_head_14266 crossref_primary_10_1111_head_14388 crossref_primary_10_1016_j_clineuro_2020_105900 crossref_primary_10_1177_1756286420927119 crossref_primary_10_1007_s10072_017_3101_8 crossref_primary_10_1038_s41582_018_0003_1 |
| Cites_doi | 10.18553/jmcp.2014.20.1.22 10.1016/S1474-4422(15)00249-5 10.1038/clpt.2011.246 10.1177/0333102411398399 10.1177/0333102414527646 10.3389/fncel.2014.00302 10.1111/bph.12129 10.1177/0333102413500727 10.1177/0333102410388435 10.1212/01.WNL.0000176298.63840.99 10.1002/ana.410330109 10.1212/WNL.58.11.1652 10.1124/jpet.115.227793 10.1001/archneur.61.4.490 10.1016/S1474-4422(14)70128-0 10.1002/acn3.197 10.1016/S1474-4422(15)00245-8 10.1517/14740338.2015.1014797 10.1212/WNL.0000000000000771 10.1212/01.wnl.0000252808.97649.21 10.1002/cne.23828 10.1016/S0140-6736(08)61626-8 10.1177/0333102410368444 10.1177/0333102414547138 10.1124/jpet.113.206458 10.1056/NEJMoa030505 10.1152/physrev.00034.2013 10.1016/S1474-4422(14)70209-1 10.1016/j.brainres.2014.11.031 10.1016/0166-2236(85)90050-5 10.1002/ana.410280213 10.1111/j.1468-2982.2008.01675.x 10.1186/1129-2377-14-S1-P224 10.1001/jama.291.8.965 10.1111/bcp.12618 |
| ContentType | Journal Article |
| Copyright | 2016 Elsevier Ltd Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Apr 2016 |
| Copyright_xml | – notice: 2016 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Apr 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U |
| DOI | 10.1016/S1474-4422(16)00019-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection (UHCL Subscription) Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Psychology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
| DatabaseTitleList | MEDLINE Neurosciences Abstracts ProQuest One Psychology |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-4465 |
| EndPage | 390 |
| ExternalDocumentID | 3983728291 26879279 10_1016_S1474_4422_16_00019_3 S1474442216000193 1_s2_0_S1474442216000193 |
| Genre | Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Amgen. |
| GroupedDBID | --- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ PUEGO ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF AADPK ABLVK ABYKQ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U |
| ID | FETCH-LOGICAL-c631t-4dd4e46341b34dd260856a575d65a6fff86c56b263d6c748f5cbcd0a0f33cdb93 |
| IEDL.DBID | 7X7 |
| ISSN | 1474-4422 |
| IngestDate | Fri Jul 11 05:35:30 EDT 2025 Wed Aug 13 06:17:17 EDT 2025 Thu Apr 03 07:05:07 EDT 2025 Tue Jul 01 02:24:37 EDT 2025 Thu Apr 24 22:57:23 EDT 2025 Fri Feb 23 02:29:00 EST 2024 Tue Feb 25 19:56:21 EST 2025 Tue Aug 26 16:34:15 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | Copyright © 2016 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c631t-4dd4e46341b34dd260856a575d65a6fff86c56b263d6c748f5cbcd0a0f33cdb93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 26879279 |
| PQID | 1772845221 |
| PQPubID | 26255 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_1776666933 proquest_journals_1772845221 pubmed_primary_26879279 crossref_citationtrail_10_1016_S1474_4422_16_00019_3 crossref_primary_10_1016_S1474_4422_16_00019_3 elsevier_sciencedirect_doi_10_1016_S1474_4422_16_00019_3 elsevier_clinicalkeyesjournals_1_s2_0_S1474442216000193 elsevier_clinicalkey_doi_10_1016_S1474_4422_16_00019_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-04-01 |
| PublicationDateYYYYMMDD | 2016-04-01 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Lancet neurology |
| PublicationTitleAlternate | Lancet Neurol |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Brandes, Saper, Diamond (bib21) 2004; 291 Vécsei, Majláth, Szok, Csáti, Tajti (bib34) 2015; 14 Russell, King, Smillie, Kodji, Brain (bib38) 2014; 94 Edvinsson, Tfelt-Hansen (bib28) 2008; 28 Dodick, Goadsby, Silberstein (bib15) 2014; 13 Edvinsson (bib24) 2015; 80 Sun, Gavva, Xu (bib33) 2015; 55 Hansen, Hauge, Olesen, Ashina (bib5) 2010; 30 Ho, Ferrari, Dodick (bib8) 2008; 372 DosSantos, Holanda-Afonso, Lima, DaSilva, Moura-Neto (bib27) 2014; 8 Vermeersch, de Hoon, De Saint-Hubert (bib29) 2013; 14 Lipton, Bigal, Diamond (bib2) 2007; 68 Hewitt, Aurora, Dodick (bib9) 2011; 31 Bigal, Dodick, Rapoport (bib13) 2015; 14 Diener, Barbanti, Dahlof, Reuter, Habeck, Podhorna (bib11) 2011; 31 Eftekhari, Gaspar, Roberts (bib23) 2016; 524 Eftekhari, Salvatore, Johansson, Chen, Zeng, Edvinsson (bib25) 2015; 1600 Marcus, Goadsby, Dodick, Stock, Manos, Fischer (bib10) 2014; 34 Vu, Ma, Chen (bib19) 2015; 55 Hepp, Dodick, Varon, Gillard, Hansen, Devine (bib35) 2015; 35 Hepp, Bloudek, Varon (bib1) 2014; 20 Goadsby, Edvinsson, Ekman (bib3) 1990; 28 Goadsby, Edvinsson (bib4) 1993; 33 (bib20) 2004; 24 Dodick, Goadsby, Spierings, Scherer, Sweeney, Grayzel (bib16) 2014; 13 de Hoon, Van Hecken, Yan (bib18) 2015; 55 Walker, Eftekhari, Bower (bib31) 2015; 2 Goadsby, Dodick, Martinez (bib37) 2015; 35 Walker, Hay (bib32) 2013; 170 Shi, Lehto, Zhu (bib17) 2016; 356 Bigal, Edvinsson, Rapoport (bib14) 2015; 14 Freitag, Collins, Carlson (bib22) 2002; 58 Ho, Connor, Zhang (bib12) 2014; 83 Silberstein, Neto, Schmitt, Jacobs (bib36) 2004; 61 Edvinnson (bib6) 1985; 8 Olesen, Diener, Husstedt (bib7) 2004; 350 Dreier, Jurkat-Rott, Petzold (bib26) 2005; 64 Chaitman, Ho, Behm (bib40) 2012; 91 Hostetler, Joshi, Sanabria-Bohorquez (bib30) 2013; 347 Bigal, Walter, Bronson, Alibhoy, Escandon (bib39) 2014; 34 Ho (10.1016/S1474-4422(16)00019-3_bib12) 2014; 83 Dodick (10.1016/S1474-4422(16)00019-3_bib16) 2014; 13 Olesen (10.1016/S1474-4422(16)00019-3_bib7) 2004; 350 Brandes (10.1016/S1474-4422(16)00019-3_bib21) 2004; 291 Ho (10.1016/S1474-4422(16)00019-3_bib8) 2008; 372 Hewitt (10.1016/S1474-4422(16)00019-3_bib9) 2011; 31 Hepp (10.1016/S1474-4422(16)00019-3_bib35) 2015; 35 (10.1016/S1474-4422(16)00019-3_bib20) 2004; 24 Goadsby (10.1016/S1474-4422(16)00019-3_bib3) 1990; 28 Shi (10.1016/S1474-4422(16)00019-3_bib17) 2016; 356 Eftekhari (10.1016/S1474-4422(16)00019-3_bib25) 2015; 1600 Sun (10.1016/S1474-4422(16)00019-3_bib33) 2015; 55 Russell (10.1016/S1474-4422(16)00019-3_bib38) 2014; 94 Walker (10.1016/S1474-4422(16)00019-3_bib32) 2013; 170 Goadsby (10.1016/S1474-4422(16)00019-3_bib4) 1993; 33 Vu (10.1016/S1474-4422(16)00019-3_bib19) 2015; 55 Chaitman (10.1016/S1474-4422(16)00019-3_bib40) 2012; 91 Dodick (10.1016/S1474-4422(16)00019-3_bib15) 2014; 13 Bigal (10.1016/S1474-4422(16)00019-3_bib13) 2015; 14 Dreier (10.1016/S1474-4422(16)00019-3_bib26) 2005; 64 Hepp (10.1016/S1474-4422(16)00019-3_bib1) 2014; 20 Eftekhari (10.1016/S1474-4422(16)00019-3_bib23) 2016; 524 Freitag (10.1016/S1474-4422(16)00019-3_bib22) 2002; 58 Diener (10.1016/S1474-4422(16)00019-3_bib11) 2011; 31 de Hoon (10.1016/S1474-4422(16)00019-3_bib18) 2015; 55 Marcus (10.1016/S1474-4422(16)00019-3_bib10) 2014; 34 Vermeersch (10.1016/S1474-4422(16)00019-3_bib29) 2013; 14 Edvinnson (10.1016/S1474-4422(16)00019-3_bib6) 1985; 8 Walker (10.1016/S1474-4422(16)00019-3_bib31) 2015; 2 Bigal (10.1016/S1474-4422(16)00019-3_bib39) 2014; 34 Goadsby (10.1016/S1474-4422(16)00019-3_bib37) 2015; 35 Edvinsson (10.1016/S1474-4422(16)00019-3_bib28) 2008; 28 Vécsei (10.1016/S1474-4422(16)00019-3_bib34) 2015; 14 Hansen (10.1016/S1474-4422(16)00019-3_bib5) 2010; 30 Bigal (10.1016/S1474-4422(16)00019-3_bib14) 2015; 14 Silberstein (10.1016/S1474-4422(16)00019-3_bib36) 2004; 61 Hostetler (10.1016/S1474-4422(16)00019-3_bib30) 2013; 347 Lipton (10.1016/S1474-4422(16)00019-3_bib2) 2007; 68 Edvinsson (10.1016/S1474-4422(16)00019-3_bib24) 2015; 80 DosSantos (10.1016/S1474-4422(16)00019-3_bib27) 2014; 8 26879278 - Lancet Neurol. 2016 Apr;15(4):347-9 |
| References_xml | – volume: 83 start-page: 958 year: 2014 end-page: 966 ident: bib12 article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention publication-title: Neurology – volume: 35 start-page: 55 year: 2015 ident: bib37 article-title: Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody publication-title: Cephalalgia – volume: 350 start-page: 1104 year: 2004 end-page: 1110 ident: bib7 article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine publication-title: N Engl J Med – volume: 31 start-page: 573 year: 2011 end-page: 584 ident: bib11 article-title: BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study publication-title: Cephalalgia – volume: 58 start-page: 1652 year: 2002 end-page: 1659 ident: bib22 article-title: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis publication-title: Neurology – volume: 14 start-page: P224 year: 2013 ident: bib29 article-title: PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy publication-title: J Headache Pain – volume: 33 start-page: 48 year: 1993 end-page: 56 ident: bib4 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol – volume: 1600 start-page: 93 year: 2015 end-page: 109 ident: bib25 article-title: Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier publication-title: Brain Res – volume: 31 start-page: 712 year: 2011 end-page: 722 ident: bib9 article-title: Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine publication-title: Cephalalgia – volume: 55 start-page: 175 year: 2015 end-page: 176 ident: bib19 article-title: Characterizing the relationship between AMG 334 concentration and capsaicin-induced increase in dermal blood flow in healthy subjects and migraine patients using pharmacokinetic-pharmacodynamic modeling publication-title: Headache – volume: 372 start-page: 2115 year: 2008 end-page: 2123 ident: bib8 article-title: Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial publication-title: Lancet – volume: 64 start-page: 2145 year: 2005 end-page: 2147 ident: bib26 article-title: Opening of the blood–brain barrier preceding cortical edema in a severe attack of FHM type II publication-title: Neurology – volume: 14 start-page: 667 year: 2015 end-page: 681 ident: bib34 article-title: Drug safety and tolerability in prophylactic migraine treatment publication-title: Expert Opin Drug Saf – volume: 34 start-page: 968 year: 2014 end-page: 976 ident: bib39 article-title: Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP publication-title: Cephalalgia – volume: 8 start-page: 302 year: 2014 ident: bib27 article-title: The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders publication-title: Front Cell Neurosci – volume: 14 start-page: 1091 year: 2015 end-page: 1100 ident: bib14 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol – volume: 13 start-page: 885 year: 2014 end-page: 892 ident: bib16 article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Neurol – volume: 24 start-page: 9 year: 2004 end-page: 160 ident: bib20 article-title: The International Classification of Headache Disorders: 2nd edition publication-title: Cephalalgia – volume: 13 start-page: 1100 year: 2014 end-page: 1107 ident: bib15 article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial publication-title: Lancet Neurol – volume: 61 start-page: 490 year: 2004 end-page: 495 ident: bib36 article-title: Topiramate in migraine prevention: results of a large controlled trial publication-title: Arch Neurol – volume: 34 start-page: 114 year: 2014 end-page: 125 ident: bib10 article-title: BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial publication-title: Cephalalgia – volume: 291 start-page: 965 year: 2004 end-page: 973 ident: bib21 article-title: Topiramate for migraine prevention: a randomized controlled trial publication-title: JAMA – volume: 14 start-page: 1081 year: 2015 end-page: 1090 ident: bib13 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol – volume: 35 start-page: 478 year: 2015 end-page: 488 ident: bib35 article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine publication-title: Cephalalgia – volume: 170 start-page: 1293 year: 2013 end-page: 1307 ident: bib32 article-title: CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? publication-title: Br J Pharmacol – volume: 347 start-page: 478 year: 2013 end-page: 486 ident: bib30 article-title: In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232 publication-title: J Pharmacol Exp Ther – volume: 20 start-page: 22 year: 2014 end-page: 33 ident: bib1 article-title: Systematic review of migraine prophylaxis adherence and persistence publication-title: J Manag Care Pharm – volume: 8 start-page: 126 year: 1985 end-page: 131 ident: bib6 article-title: Functional role of perivascular peptides in the control of cerebral circulation publication-title: Trends Neurosci – volume: 91 start-page: 459 year: 2012 end-page: 466 ident: bib40 article-title: A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina publication-title: Clin Pharmacol Ther – volume: 80 start-page: 193 year: 2015 end-page: 199 ident: bib24 article-title: CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment publication-title: Br J Clin Pharmacol – volume: 30 start-page: 1179 year: 2010 end-page: 1186 ident: bib5 article-title: Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura publication-title: Cephalalgia – volume: 356 start-page: 223 year: 2016 end-page: 231 ident: bib17 article-title: Pharmacological characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor publication-title: J Pharmacol Exp Ther – volume: 55 start-page: 252 year: 2015 ident: bib33 article-title: Inhibitors of CGRP function differentially affect calcitonin-family ligand/receptor interactions publication-title: Headache – volume: 55 start-page: 174 year: 2015 end-page: 175 ident: bib18 article-title: Single-dose and multiple dose, phase 1, randomized, double-blind, placebo-controlled studies of AMG 334 in healthy subjects and migraine patients publication-title: Headache – volume: 28 start-page: 1245 year: 2008 end-page: 1258 ident: bib28 article-title: The blood–brain barrier in migraine treatment publication-title: Cephalalgia – volume: 28 start-page: 183 year: 1990 end-page: 187 ident: bib3 article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache publication-title: Ann Neurol – volume: 2 start-page: 595 year: 2015 end-page: 608 ident: bib31 article-title: A second trigeminal CGRP receptor: function and expression of the AMY1 receptor publication-title: Ann Clin Transl Neurol – volume: 94 start-page: 1099 year: 2014 end-page: 1142 ident: bib38 article-title: Calcitonin gene-related peptide: physiology and pathophysiology publication-title: Physiol Rev – volume: 68 start-page: 343 year: 2007 end-page: 349 ident: bib2 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology – volume: 524 start-page: 90 year: 2016 end-page: 118 ident: bib23 article-title: Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography publication-title: J Comp Neurol – volume: 20 start-page: 22 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib1 article-title: Systematic review of migraine prophylaxis adherence and persistence publication-title: J Manag Care Pharm doi: 10.18553/jmcp.2014.20.1.22 – volume: 14 start-page: 1081 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib13 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(15)00249-5 – volume: 91 start-page: 459 year: 2012 ident: 10.1016/S1474-4422(16)00019-3_bib40 article-title: A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.246 – volume: 55 start-page: 175 issue: suppl S3 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib19 article-title: Characterizing the relationship between AMG 334 concentration and capsaicin-induced increase in dermal blood flow in healthy subjects and migraine patients using pharmacokinetic-pharmacodynamic modeling publication-title: Headache – volume: 31 start-page: 712 year: 2011 ident: 10.1016/S1474-4422(16)00019-3_bib9 article-title: Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine publication-title: Cephalalgia doi: 10.1177/0333102411398399 – volume: 55 start-page: 174 issue: suppl S3 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib18 article-title: Single-dose and multiple dose, phase 1, randomized, double-blind, placebo-controlled studies of AMG 334 in healthy subjects and migraine patients publication-title: Headache – volume: 34 start-page: 968 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib39 article-title: Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP publication-title: Cephalalgia doi: 10.1177/0333102414527646 – volume: 8 start-page: 302 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib27 article-title: The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders publication-title: Front Cell Neurosci doi: 10.3389/fncel.2014.00302 – volume: 170 start-page: 1293 year: 2013 ident: 10.1016/S1474-4422(16)00019-3_bib32 article-title: CGRP in the trigeminovascular system: a role for CGRP, adrenomedullin and amylin receptors? publication-title: Br J Pharmacol doi: 10.1111/bph.12129 – volume: 35 start-page: 55 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib37 article-title: Onset of efficacy of LY2951742 in migraine prevention: post-hoc analysis of phase 2a, randomized, double-blind, placebo-controlled study data of a calcitonin gene-related peptide monoclonal antibody publication-title: Cephalalgia – volume: 34 start-page: 114 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib10 article-title: BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial publication-title: Cephalalgia doi: 10.1177/0333102413500727 – volume: 31 start-page: 573 year: 2011 ident: 10.1016/S1474-4422(16)00019-3_bib11 article-title: BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study publication-title: Cephalalgia doi: 10.1177/0333102410388435 – volume: 64 start-page: 2145 year: 2005 ident: 10.1016/S1474-4422(16)00019-3_bib26 article-title: Opening of the blood–brain barrier preceding cortical edema in a severe attack of FHM type II publication-title: Neurology doi: 10.1212/01.WNL.0000176298.63840.99 – volume: 33 start-page: 48 year: 1993 ident: 10.1016/S1474-4422(16)00019-3_bib4 article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats publication-title: Ann Neurol doi: 10.1002/ana.410330109 – volume: 58 start-page: 1652 year: 2002 ident: 10.1016/S1474-4422(16)00019-3_bib22 article-title: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis publication-title: Neurology doi: 10.1212/WNL.58.11.1652 – volume: 356 start-page: 223 year: 2016 ident: 10.1016/S1474-4422(16)00019-3_bib17 article-title: Pharmacological characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.115.227793 – volume: 61 start-page: 490 year: 2004 ident: 10.1016/S1474-4422(16)00019-3_bib36 article-title: Topiramate in migraine prevention: results of a large controlled trial publication-title: Arch Neurol doi: 10.1001/archneur.61.4.490 – volume: 24 start-page: 9 issue: suppl 1 year: 2004 ident: 10.1016/S1474-4422(16)00019-3_bib20 article-title: The International Classification of Headache Disorders: 2nd edition publication-title: Cephalalgia – volume: 13 start-page: 885 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib16 article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70128-0 – volume: 2 start-page: 595 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib31 article-title: A second trigeminal CGRP receptor: function and expression of the AMY1 receptor publication-title: Ann Clin Transl Neurol doi: 10.1002/acn3.197 – volume: 14 start-page: 1091 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib14 article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(15)00245-8 – volume: 14 start-page: 667 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib34 article-title: Drug safety and tolerability in prophylactic migraine treatment publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.2015.1014797 – volume: 83 start-page: 958 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib12 article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention publication-title: Neurology doi: 10.1212/WNL.0000000000000771 – volume: 55 start-page: 252 issue: suppl S5 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib33 article-title: Inhibitors of CGRP function differentially affect calcitonin-family ligand/receptor interactions publication-title: Headache – volume: 68 start-page: 343 year: 2007 ident: 10.1016/S1474-4422(16)00019-3_bib2 article-title: Migraine prevalence, disease burden, and the need for preventive therapy publication-title: Neurology doi: 10.1212/01.wnl.0000252808.97649.21 – volume: 524 start-page: 90 year: 2016 ident: 10.1016/S1474-4422(16)00019-3_bib23 article-title: Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: a detailed study using in situ hybridization, immunofluorescence, and autoradiography publication-title: J Comp Neurol doi: 10.1002/cne.23828 – volume: 372 start-page: 2115 year: 2008 ident: 10.1016/S1474-4422(16)00019-3_bib8 article-title: Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial publication-title: Lancet doi: 10.1016/S0140-6736(08)61626-8 – volume: 30 start-page: 1179 year: 2010 ident: 10.1016/S1474-4422(16)00019-3_bib5 article-title: Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura publication-title: Cephalalgia doi: 10.1177/0333102410368444 – volume: 35 start-page: 478 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib35 article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine publication-title: Cephalalgia doi: 10.1177/0333102414547138 – volume: 347 start-page: 478 year: 2013 ident: 10.1016/S1474-4422(16)00019-3_bib30 article-title: In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232 publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.113.206458 – volume: 350 start-page: 1104 year: 2004 ident: 10.1016/S1474-4422(16)00019-3_bib7 article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine publication-title: N Engl J Med doi: 10.1056/NEJMoa030505 – volume: 94 start-page: 1099 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib38 article-title: Calcitonin gene-related peptide: physiology and pathophysiology publication-title: Physiol Rev doi: 10.1152/physrev.00034.2013 – volume: 13 start-page: 1100 year: 2014 ident: 10.1016/S1474-4422(16)00019-3_bib15 article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70209-1 – volume: 1600 start-page: 93 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib25 article-title: Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier publication-title: Brain Res doi: 10.1016/j.brainres.2014.11.031 – volume: 8 start-page: 126 year: 1985 ident: 10.1016/S1474-4422(16)00019-3_bib6 article-title: Functional role of perivascular peptides in the control of cerebral circulation publication-title: Trends Neurosci doi: 10.1016/0166-2236(85)90050-5 – volume: 28 start-page: 183 year: 1990 ident: 10.1016/S1474-4422(16)00019-3_bib3 article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache publication-title: Ann Neurol doi: 10.1002/ana.410280213 – volume: 28 start-page: 1245 year: 2008 ident: 10.1016/S1474-4422(16)00019-3_bib28 article-title: The blood–brain barrier in migraine treatment publication-title: Cephalalgia doi: 10.1111/j.1468-2982.2008.01675.x – volume: 14 start-page: P224 year: 2013 ident: 10.1016/S1474-4422(16)00019-3_bib29 article-title: PET imaging in healthy subjects and migraineurs suggests CGRP receptor antagonists do not have to act centrally to achieve clinical efficacy publication-title: J Headache Pain doi: 10.1186/1129-2377-14-S1-P224 – volume: 291 start-page: 965 year: 2004 ident: 10.1016/S1474-4422(16)00019-3_bib21 article-title: Topiramate for migraine prevention: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.291.8.965 – volume: 80 start-page: 193 year: 2015 ident: 10.1016/S1474-4422(16)00019-3_bib24 article-title: CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.12618 – reference: 26879278 - Lancet Neurol. 2016 Apr;15(4):347-9 |
| SSID | ssj0021481 |
| Score | 2.6188362 |
| Snippet | The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and... Summary Background The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the... Background The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 382 |
| SubjectTerms | Adult Analgesics Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Clinical trials Double-Blind Method Female Headaches Humans Immunoglobulins Immunologic Factors - administration & dosage Immunologic Factors - adverse effects Immunologic Factors - pharmacology Ligands Male Middle Aged Migraine Migraine Disorders - prevention & control Neurology Outcome Assessment (Health Care) Peptides Prevention Receptors, Calcitonin Gene-Related Peptide - antagonists & inhibitors Studies |
| Title | Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1474442216000193 https://www.clinicalkey.es/playcontent/1-s2.0-S1474442216000193 https://dx.doi.org/10.1016/S1474-4422(16)00019-3 https://www.ncbi.nlm.nih.gov/pubmed/26879279 https://www.proquest.com/docview/1772845221 https://www.proquest.com/docview/1776666933 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaglRAXxJstpTISB5Aw3cSO43BBBbVUSFshSqW9WfGrVFqSlOweeuSfM-N4sxdKueX12UrG8XzOTOYj5JX0CmY5aVlp8sCEUwVDYW3mZCUKVYfKeozozk7k8Zn4Mi_m6YNbn9Iq13NinKhda_Eb-X4GNFBh-e_sQ3fJUDUKo6tJQuM22cbSZZjSVc43Cy6g-nHBJUrBhMjzzR88-6fjwdeZfBOZDuPX-abruGf0QUf3yb1EHunBYO0H5JZvHpI7sxQef0R-n9bBL69o3TjqsTZEba9oG-jB7DPlXFAgqLRLNZvaBs_47qJvAU5_XpyjWIR_T2sK7su1YH_v3lLXrszCMwNsFPZiBpdpWUpwX-AV3Q9whDSnUf_jMTk7Ovz-6ZgljQVmJc-WYB0nvJDgywyHbVjdqELWwOGcLGoZQlDSFtLkkjtpS6FCYY1103oaOLfOVPwJ2Wraxj8jNMRidSLLLLTonFG-9hVKXFUoisXNhIj109U2FSBHHYyFHjPN0CgajaIzGcPileYT8m6EdUMFjpsAcm06vf69FCZEDT7iJmD5N6Dv02vd60z3uZ4OaATDDSMUkGpEJuYyMJL_6XR3Pbr0pp9xsE_Iy_E0GB6jOXXj21W8BpaesuLQxNNhVI7PJ5eqrPKy2vl348_JXeB_ckhE2iVby18r_wI41tLsxRdpj2x_PDz5-u0P57gdLA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELaqVAIuiDcpBYwEEki4zdperxcJoQItKW0iRFupN-PX0kphd2EToRz5Q_xGxvvqhVIuvSXZ_byJZzz-JjOeQeip8BKsnLAkMTQj3MmYhMbaxImUx1JnqfUhojuZivER_3gcH6-g391ZmJBW2dnE2lC7wob_yDcjoIEylP-O3pTfSegaFaKrXQuNRi32_PInuGzV6933IN9nlO5sH74bk7arALGCRXP4Po57LsB6Gwavgc_LWGhgLU7EWmRZJoWNhaGCOWETLrPYGutGepQxZp0JxZfA5K9yBq7MAK2-3Z5--ty7eOBc1C4eTzjhnNKzM0ObB_2HzyPxouZWhJ23G57Hdutdb-cGut7SVbzV6NdNtOLzW-jKpA3I30a_DnTm50usc4d9qEah7RIXGd6afMCMcQyUGJdtlagiD1d8eVoVAMffTr-G9hT-FdYYNkxXgMZ59xK7YmFmnhjgv_CuzhkzBWlT6mfhjvIEtl5Mcd1x5A46upT5v4sGeZH7-whndXk8HkUWRnTOSK99GppqpaENFzNDxLvZVbYteR46b8xUn9sWhKKCUFQk6kB8qtgQbfSwsqn5cRFAdKJT3YFWMMEKdqWLgMnfgL5qDUmlIlVRNWrQAQw_OEABKXtky5UaDvQ_D13vtEudPadfXkP0pL8Mgg_xI537YlHfA86uSBkMca_Ryn5-qJBJSpN07d-DP0ZXx4eTfbW_O917gK4B-xRNGtQ6Gsx_LPxDYHhz86hdVhh9ueyV_Ae6j1ph |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VRaq4IN6EFlgkkEBiSexdr9dICFWU0FJSIZVKuS3eF60U7IAToRz5W_w6ZvzKhVIuvSWxZ53svL7JzM4Q8kR6BVZOWpaaODDhVMJwsDZzMhOJykNmPWZ0J0dy_0R8mCbTDfK7OwuDZZWdTawNtSst_kc-jAAGKmz_HQ1DWxbxaW_8Zv6d4QQpzLR24zQaETn0q58QvlWvD_aA10_jePzu89t91k4YYFbyaAHfzQkvJFhyw-E1YHuVyBwQjJNJLkMIStpEmlhyJ20qVEissW6UjwLn1hlsxATm_0rKkwh1LJ2ugz0IM-pgT6SCCRHH69NDw-P-w2eRfF6jLMbP84vn4d7a_42vk2stcKW7jaTdIBu-uEm2Jm1q_hb5dZwHv1jRvHDUY1-K3K5oGeju5D3lXFAAx3Te9osqC7zi52dVCeT029lXHFThX9Gcgut0Jciedy-oK5dm5pkBJAzv6uoxU7K2uH6Gd8xPwQnTmNazR26Tk0vZ_TtksygLf4_QUDfKE1FkYUXnjPK5z3C8VoYDubgZENHtrrZt83OcwTHTfZUbMkUjU3Qk65R8pvmAvOzJ5k33j4sIZMc63R1tBWOswT9dRJj-jdBXrUmpdKSrWI8aaiSGH4ykQKl6yhY1NWjofx6600mXXj-nV7QBedxfBsZjJikvfLms74GwV2YclrjbSGW_P7FUaRan2f1_L_6IbIH-6o8HR4fb5CrAUNnUQ-2QzcWPpX8AUG9hHtY6RcmXy1biP2NYXTE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+efficacy+of+AMG+334+for+prevention+of+episodic+migraine%3A+a+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial&rft.jtitle=Lancet+neurology&rft.au=Sun%2C+Hong&rft.au=Dodick%2C+David+W&rft.au=Silberstein%2C+Stephen&rft.au=Goadsby%2C+Peter+J&rft.date=2016-04-01&rft.issn=1474-4422&rft.volume=15&rft.issue=4&rft.spage=382&rft.epage=390&rft_id=info:doi/10.1016%2FS1474-4422%2816%2900019-3&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-4422&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-4422&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-4422&client=summon |